TL;DR
This study investigates the efficacy of two chemotherapy combinations (brentuximab vedotin-ICE and romidepsin-ICE) as salvage therapy for relapsed/refractory peripheral T-cell lymphoma (R/R PTCL), a challenging disease with poor prognosis. The findings suggest that tailoring treatment based on CD30 expression (brentuximab for CD30+, romidepsin for CD30-) is a feasible and effective strategy, showing promising response rates and the potential to bridge patients to stem cell transplantation.
What Problem Does This Paper Address?
Peripheral T-cell lymphoma (PTCL) is a group of aggressive blood cancers that often relapse or become resistant to initial treatments, leading to a poor prognosis. Currently, there's no universally established standard of care for these relapsed/refractory (R/R) cases. While the ICE (ifosfamide, carboplatin, etoposide) chemotherapy regimen has shown some success in other lymphomas, its use in R/R PTCL, especially in combination with newer targeted agents, has been limited. Romidepsin and brentuximab vedotin are FDA-approved drugs for R/R PTCL, but their effectiveness as single agents is modest. This paper aims to address the gap in understanding how these targeted agents, when combined with ICE, perform in R/R PTCL, particularly by stratifying treatment based on CD30 expression, a marker found on some PTCL cells.
Methods
This was a retrospective study conducted at a single cancer center. Researchers analyzed medical records of 13 patients with R/R PTCL treated between May 2016 and September 2019. The treatment strategy was guided by CD30 expression: patients with CD30-positive PTCL received brentuximab vedotin combined with ICE (Bv-ICE), while those with CD30-negative PTCL received romidepsin combined with ICE (Ro-ICE). The ICE regimen consisted of ifosfamide, carboplatin, and etoposide, administered intravenously. Brentuximab vedotin was given at 1.5 mg/kg on days 1 and 8, and romidepsin was given at 8 mg/m² on days 1 and 4, with both regimens administered in 21-day cycles. Dose modifications were allowed at the physician's discretion. The primary objective was to assess the overall response rate (ORR), with secondary objectives including duration of response (DOR), stem cell transplant rates, and toxicities. Response was evaluated using CT or PET scans, and toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Datasets
The study utilized data from the medical records of 13 patients treated at the Houston Methodist Cancer Center. No new datasets or benchmarks were introduced.
Key Insights and Ideas
- CD30-guided therapy is feasible and effective: The core idea is that tailoring salvage chemotherapy based on CD30 expression can lead to better outcomes in R/R PTCL. This personalized approach leverages the known targets of brentuximab vedotin.
- Combination therapy enhances response: Combining ICE with either brentuximab vedotin or romidepsin appears to significantly improve response rates compared to single-agent therapies, offering a much-needed option for patients with refractory disease.
- Bridging to transplant: Both regimens demonstrated the potential to induce responses that allowed a substantial proportion of patients to proceed to consolidation with stem cell transplantation, a critical step for long-term survival in PTCL.
- Tolerability of combinations: Despite the aggressive nature of the regimens, most patients tolerated the treatment well, with manageable toxicities, although specific toxicity profiles differed between the two combinations.
Key Results
- Overall Response Rates (ORR): Bv-ICE achieved an ORR of 66.7%, with all patients achieving a complete response (CR). Ro-ICE showed an ORR of 71.4%, with 57.1% achieving a CR.
- Complete Remission (CR): Notably, the Bv-ICE group had a 100% CR rate, while the Ro-ICE group had a 57.1% CR rate.
- Duration of Response (DOR): The median DOR was 7.5 months for Bv-ICE and 6 months for Ro-ICE.
- Stem Cell Transplantation: A significant portion of patients proceeded to consolidation with stem cell transplant: 33.3% in the Bv-ICE group and 42.9% in the Ro-ICE group.
- Toxicities: Cytopenias were common in both groups. Severe neutropenia was more frequent with Bv-ICE (83.3%) compared to Ro-ICE (42.9%). However, grade 3-4 anemia and thrombocytopenia were more prevalent with Ro-ICE. Metabolic abnormalities were generally lower and primarily related to liver function.
Limitations and Future Work
The authors acknowledge that this is a small, retrospective study from a single institution, which limits the generalizability of the findings. The small sample size also makes it difficult to draw definitive conclusions about the long-term efficacy and safety of these regimens.
Future work should focus on conducting larger, prospective, multi-center trials to validate these findings. Further research is also needed to:
- Better understand the role of CD30 expression as a predictive biomarker.
- Optimize dosing and scheduling of these combination regimens.
- Compare these strategies directly against other salvage therapies.
- Investigate the long-term outcomes, including survival and quality of life, for patients treated with these regimens.
Summary updated